• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA ups post-market scrutiny of spinal implant systems

FDA ups post-market scrutiny of spinal implant systems

October 6, 2009 By MassDevice staff

The Food & Drug Administration is requiring manufacturers of dynamic stabilization systems to run post-market studies examining fusion rates and the frequency of additional surgeries after implantation.

The federal safety watchdog said the systems, which use pedicle screws to stabilize spinal vertebrae, are designed to fortify the spine while fractured or otherwise damaged vertebrae heal. The systems are meant to allow some flexibility during the fusing process, compared with older systems that fix the spine in place and allow for no movement.

“Currently, there is not enough clinical data to determine whether these dynamic stabilization systems provide enough spinal stability to allow for complete spinal fusion, as the system components may loosen, bend, or break over time. If fusion does not occur, a patient’s condition could worsen and possibly require additional surgical procedures,” the FDA said in a press release.

Besides the new post-market requirements for existing systems, the agency is also requiring makers of new products to supply additional data along with their approval submissions.

No changes are expected regarding how the devices may be used, at least until it’s had a chance to review the data, the agency said.

The 16 manufacturers of already-approved systems must design and implement studies to examine:

  • The fusion rate for dynamic stabilization systems compared to traditional stabilization systems;
  • The incidence rate, severity and time course of adverse events for dynamic stabilization systems compared to traditional stabilization systems;
  • The type, incidence rate and time course of subsequent surgical procedures for dynamic stabilization systems compared to traditional stabilization systems;
  • And the cause of failure for dynamic stabilization systems based on analysis of all reasonable available systems that have been removed from patients, along with any association between the patient’s demographic and clinical data and the device failure.

The new requirement is the latest sign that the FDA’s new regime plans to hold medical device makers to a higher standard. In August, new commissioner Margaret Hamburg said the agency would step up its enforcement efforts and act more quickly in cases where public health might be at risk.

The agency will have more resources to implement that plan, as well, after the U.S. Congress approved a $373 million, 14 percent budget boost for 2010.

Filed Under: Business/Financial News Tagged With: Gift Bans

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy